Steinbach et al. conducted a randomized trial that demonstrated a significant reduction in colorectal polyp burden in FAP patients treated with celecoxib, a COX-2 inhibitor, compared to placebo [16]. The gene discussed is PTGS2; the disease is polyp of large intestine.